Free Trial
NASDAQ:GYRE

Gyre Therapeutics Q4 2024 Earnings Report

Gyre Therapeutics logo
$9.26 -0.08 (-0.86%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$9.26 0.00 (-0.05%)
As of 05/2/2025 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gyre Therapeutics EPS Results

Actual EPS
$0.01
Consensus EPS
$0.04
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Gyre Therapeutics Revenue Results

Actual Revenue
$27.87 million
Expected Revenue
$23.50 million
Beat/Miss
Beat by +$4.37 million
YoY Revenue Growth
N/A

Gyre Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 17, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Gyre Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Gyre Therapeutics Earnings Headlines

Gyre Therapeutics announces NMPA approval for trial on pirfenidone
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE), a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

View Gyre Therapeutics Profile

More Earnings Resources from MarketBeat